Biospecifics Technologies Revenue Growth Rates (BSTC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biospecifics Technologies Corp  (NASDAQ: BSTC)
 

BSTC's Revenue Growth by Quarter and Year

Biospecifics Technologies's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BSTC Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September 11.26
2nd Quarter June 3.90
1st Quarter March 9.67
FY 24.83

BSTCs Annual Revenue
Biospecifics Technologies's Revenue in the fiscal year 2019 $ 38.19 millions
Biospecifics Technologies's Revenue in the fiscal year 2018 $ 32.96 millions
Biospecifics Technologies's Revenue in the fiscal year 2017 $ 27.44 millions
Biospecifics Technologies's Revenue in the fiscal year 2016 $ 26.25 millions
Biospecifics Technologies's Revenue in the fiscal year 2015 $ 22.75 millions




BSTC Revenue third quarter 2020 Y/Y Growth Comment
Biospecifics Technologies Corp reported Revenue increase of 19.24% year on year in the third quarter 2020, to $ 11.26 millions, this is lower than Biospecifics Technologies Corp's recent average Revenue improvement of 20.41%.

Looking into third quarter 2020 results within Major Pharmaceutical Preparations industry 97 other companies have achieved higher Revenue growth. While Biospecifics Technologies Corp' s Revenue growth of 19.24% ranks overall at the positon no. 899 in the third quarter 2020.


BSTC Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 10.84 % 58.36 % 1.21 %
3rd Quarter September 19.24 % 15.54 % 25.31 % -5.23 %
2nd Quarter June -55.93 % 24.65 % 8.56 % 5.83 %
1st Quarter March 18.94 % 14.67 % -7.8 % 17.05 %
FY   - 15.8 % 20.11 % -

Financial Statements
Biospecifics Technologies's third quarter 2020 Revenue $ 11.26 millions BSTC's Income Statement
Biospecifics Technologies's third quarter 2019 Revenue $ 9.44 millions Quarterly BSTC's Income Statement


BSTC Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - 24.58 % 29.87 % 2.76 %
3rd Quarter September 188.61 % 6.67 % 15.07 % -0.31 %
2nd Quarter June -59.67 % 8.86 % 0.14 % -14.95 %
1st Quarter March -17.77 % -23.37 % 5.82 % 16.16 %
FY (Year on Year)   - 15.8 % 20.11 % -


Back to BSTC Growth rate Comparisons >> Back to BSTC Growth rate Comparisons >>


Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #98
Healthcare Sector #213
Overall #899

Revenue Y/Y Growth Statistics
High Average Low
103.04 % 20.41 % -55.91 %
(Mar 31 2015)   (Jun 30 2020)
Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #98
Healthcare Sector #213
Overall #899
Revenue Y/Y Growth Statistics
High Average Low
103.04 % 20.41 % -55.91 %
(Mar 31 2015)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Biospecifics Technologies's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
188.36 % 10.39 % -59.63 %
 


BSTC's III. Quarter Q/Q Revenue Comment
Biospecifics Technologies Corp achieved in the III. Quarter 2020 above company average sequential Revenue doubling of 188.61%, to $ 11.26 millions, from $3.90 millions in the second quarter.
BSTC is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Revenue quarter on quarter growth. While Biospecifics Technologies's Revenue growth quarter on quarter, overall rank is 160.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #50
Overall #160
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #50
Overall #160
Revenue Q/Q Growth Statistics
High Average Low
188.36 % 10.39 % -59.63 %
 


BSTC's III. Quarter Q/Q Revenue Comment
Biospecifics Technologies Corp achieved in the III. Quarter 2020 above company average sequential Revenue doubling of 188.61%, to $ 11.26 millions, from $3.90 millions in the second quarter.
BSTC is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Revenue quarter on quarter growth. While Biospecifics Technologies's Revenue growth quarter on quarter, overall rank is 160.


Biospecifics Technologies's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)
Cumulative Revenue 12 Months Ending $ 36.59 $ 34.78 $ 39.73 $ 38.19 $ 37.03
Y / Y Revenue Growth (TTM) -1.19 % -2.74 % 16.84 % 15.86 % 27.45 %
Year on Year Revenue Growth Overall Ranking # 1781 # 1777 # 775 # 322 # 1380
Seqeuential Revenue Change (TTM) 5.21 % -12.46 % 4.03 % 3.12 % 3.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 1375 # 2903 # 692 # 1359 # 1187


Cumulative Revenue growth Comment
Biospecifics Technologies showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2020. If the fiscal year would end in Sep 30 2020, Biospecifics Technologies's annual Revenue improvement would be -1.19% year on year to $37 millions.

In the Healthcare sector 299 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1777 to 1781.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 102
Healthcare Sector # 300
Overall # 1781

Revenue TTM Y/Y Growth Statistics
High Average Low
61.61 %
 18.75 %
-4.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 102
Sector # 233
S&P 500 # 1375
Cumulative Revenue growth Comment
Biospecifics Technologies showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2020. If the fiscal year would end in Sep 30 2020, Biospecifics Technologies's annual Revenue decline would be -1.19% year on year to $37 millions.

In the Healthcare sector 299 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1777 to 1781.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 102
Healthcare Sector # 300
Overall # 1781

Revenue TTM Y/Y Growth Statistics
High Average Low
61.61 %
18.75 %
-4.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 102
Sector # 233
S&P 500 # 1375




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BSTC's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Sep 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2020
Orasure Technologies Inc33.40%$ 33.405 millions
Cumberland Pharmaceuticals Inc 33.38%$ 33.384 millions
Agios Pharmaceuticals Inc 33.36%$ 33.362 millions
Labcorp Holdings Inc 33.04%$ 33.041 millions
Integrated Biopharma Inc33.02%$ 33.018 millions
Remedent Inc 32.99%$ 32.987 millions
Kyntra Bio Inc 32.73%$ 32.730 millions
Kaya Holdings Inc 31.67%$ 31.671 millions
Irhythm Holdings Inc 31.59%$ 31.590 millions
Tandem Diabetes Care Inc 30.58%$ 30.580 millions
Biodelivery Sciences International Inc 30.15%$ 30.149 millions
Ascendis Pharma A29.30%$ 29.303 millions
Schrodinger Inc 29.24%$ 29.243 millions
Jrsis Health Care Corp29.02%$ 29.020 millions
Q32 Bio Inc 28.57%$ 28.571 millions
Intercept Pharmaceuticals inc 28.36%$ 28.363 millions
Allied Healthcare Products inc 27.76%$ 27.758 millions
Advanced Container Technologies Inc 27.69%$ 27.694 millions
Acadia Pharmaceuticals Inc 27.48%$ 27.479 millions
Cerus Corporation27.43%$ 27.433 millions
Catalent Inc 27.23%$ 27.230 millions
Option Care Health Inc 26.91%$ 26.909 millions
Dexcom Inc 26.39%$ 26.394 millions
Meridian Bioscience Inc 26.17%$ 26.171 millions
Natera Inc 25.97%$ 25.971 millions
Si bone inc 25.90%$ 25.899 millions
Alexion Pharmaceuticals Inc 25.78%$ 25.778 millions
Immucell Corporation25.32%$ 25.316 millions
Lemaitre Vascular Inc 25.14%$ 25.141 millions
Geovax Labs Inc 24.68%$ 24.684 millions


About Biospecifics Technologies Revenue Growth Rates (BSTC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.